DiaMedica Therapeutics (DMAC) Q3 2026 earnings review
DiaMedica hits its stroke trial target, but cash burn rises
DiaMedica Therapeutics, a clinical-stage drugmaker developing a single protein therapy for stroke and pregnancy disorders, hit its key enrollment target while burning cash faster. Chief executive Rick Pauls confirmed that its stroke trial passed 200 patients, locking in the first-quarter 2027 interim check, and its fetal growth study finished enrolling a second dose group for a November 24 readout. However, quarterly research spending rose to $9 million, and by our math operating cash burn reached nearly $9 million, leaving $35 million in the bank.
| ReMEDy2 stroke interim cohort | 100% enrolled 85% as of August 1 |
|---|---|
| Cash and marketable securities | $34.9M down from $43.5M in Q2 |
| Operating cash burn (derived) | $8.8M up from $8.1M in Q2 |
| Cash runway outlook | Trimmed "into Q4 2027" vs "through 2027" prior |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because clinical progress balanced out a tighter cash clock. Enrolling the 200th stroke patient removes the delay risk that pushed the interim readout back three times, but management quietly trimmed its cash outlook from "through 2027" to "into Q4, 2027" as trial bills climbed.
The question now is whether the independent safety board keeps the stroke trial near 300 patients or expands it toward 728, which would require fresh funding much sooner. Either the current cash carries the study deep into next year, or a larger patient target forces a share sale right after the readout. The first-quarter 2027 interim decision will settle it.
🐂 Bull Case
Stroke Trial Reaches 200-Patient Target for Interim Readout
DiaMedica's largest study is ReMEDy2, a mid-to-late-stage trial testing its only drug, DM199, in patients with acute ischemic stroke, where a blood clot blocks oxygen to the brain. After pushing the target date back three times over the past two years, chief executive Rick Pauls confirmed "reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2".
Hitting the 200-patient mark starts a fixed clock. Once the 200th patient finishes a 90-day recovery check, an independent safety board will review the data in the first quarter of 2027. That takes enrollment speed off the table as a near-term delay risk for the check-in, though the board could still stop the study early or expand it from 300 patients toward 728.
What to watch: the independent board's decision in the first quarter of 2027. A green light near the minimum 300-patient size would allow the drugmaker to finish the trial without raising massive new funds.
Fetal Growth Study Finishes Second Cohort Ahead of Schedule
The company is increasingly focusing on pregnancy disorders, including fetal growth restriction (FGR), where poor blood flow in the placenta keeps an unborn baby from growing normally. DiaMedica had planned to share data from its first six-patient group in September, but held the event back until November 24 after completing enrollment in both the first and second dose groups.
Having 12 patients across two dose levels (5 and 10 micrograms per kilogram) gives doctors a fuller look at whether the mid-level dose improves blood flow better than higher doses. Caution is still warranted because this South African trial has no comparison group and tests a small number of mothers, so early signals can look noisier than they would in a larger study.
What to watch: blood-flow and safety measurements from the first 12 patients at the November 24 online event. Clear improvement without blood-pressure drops would support the dose choices for the upcoming preeclampsia trials.
Canada and Europe Clear Early-Onset Preeclampsia Trial
Preeclampsia is a life-threatening spike in pregnancy blood pressure, and DiaMedica wants to run its own 30-patient study in women who develop it early. While US regulators have held up the trial over animal testing questions, Health Canada cleared the study in September and the European Medicines Agency gave conditional approval in October.
Opening sites in Canada, Europe and potentially the United Kingdom lets the biotech group gather multi-country data without waiting for Washington. However, management dropped its earlier promise to dose the first Canadian patient before year-end, saying only that it is preparing to start.
What to watch: the date the first patient receives a dose in Canada. Dosing before the first quarter of 2027 ends would show the international backup plan is working on the ground.
🐻 Bear Case
Cash Burn Rises and Trims the 2027 Cash Outlook
DiaMedica has no product sales and funds its trials from a shrinking pile of cash and marketable securities, which ended September at $34.9 million. For the past two quarters, management said its cash would fund operations "through 2027", but the release quietly pulled that target back, stating that cash "will enable the Company to fund its planned clinical studies and support corporate operations into Q4, 2027".
- Third-quarter operating cash burn: $8.8 million by our math, up from $8.1 million in the second quarter
- Research and development spending: $9.2 million, up 13.4% from last quarter and 43.6% from a year ago
- Remaining cash and securities: $34.9 million, equal to 4.0 quarters of spending at the third-quarter pace by our math
The change in wording matters because research spending rose faster than the 10% quarterly cap the finance chief previously defined as moderate, and management expects another increase next quarter. By our math, $34.9 million runs out right as the fourth quarter of 2027 begins even if spending stops rising, leaving very little cushion after the first-quarter stroke readout.
What to watch: fourth-quarter operating cash burn in the annual report. A burn rate above $9 million would mean DiaMedica needs to sell shares or find a partner during the first half of 2027.
Rat Study Delays Push Back US Preeclampsia Application
To open preeclampsia trial sites in the United States, DiaMedica must convince the Food and Drug Administration that an older reproductive safety study in rats is sufficient. That requires new lab tests to "demonstrate adequate DM199 exposure, enzymatic activity, and pharmacologic effect in rats".
Last quarter, chief executive Rick Pauls expected to finish the rat study in September and have the final reports in October. Instead, the release said only that "pharmacokinetic and pharmacologic results are due in the coming weeks". In parallel, two follow-on cohorts in the South African preeclampsia trial slipped from a September or October start to the end of 2026.
What to watch: the date DiaMedica submits the rat data package to US regulators. Another delay past year-end would keep US clinical sites closed well into 2027.
Risks this quarter didn't answer
Two core risks around the company's single drug candidate remain open ahead of next year's readouts.
- Single-drug reliance: every trial tests DM199, a synthetic version of the human KLK1 protein; the November 24 fetal growth readout and first-quarter stroke check are the next tests of whether the mechanism works.
- Stroke trial resizing or termination: the safety board remains blinded to the company until the first quarter of 2027, when it will decide whether to stop ReMEDy2 for lack of benefit or expand enrollment between 300 and 728 patients.
💲 Other KPIs
The quarterly loss widened by 31.2% from $8.6 million a year ago, and rose from $10.1 million in the second quarter. Basic and diluted loss per share reached $0.21, compared with $0.17 a year ago, as global stroke trial expansion and pregnancy study start-up costs pushed operating expenses higher.
Working capital — short-term assets minus bills due within a year — dropped 25.7% from $37.7 million in the second quarter and is down by nearly half from $55.5 million at year-end. Alongside cash spending, current liabilities rose 13.0% from last quarter to $7.5 million on higher accrued trial bills.
Overhead spending fell 8.4% from $2.6 million a year ago and stayed nearly flat against $2.3 million in the second quarter. Lower legal and outside professional bills offset non-cash stock compensation across the company, which rose 50.9% from a year ago to $1.5 million in the third quarter by our math.
🔮 Guidance
Cut. Management now says its $34.9 million in cash and securities will fund planned studies "into Q4, 2027", trimming the prior "through 2027" wording. By our math, the third-quarter operating cash burn of $8.8 million leaves 3.95 quarters of cash, which reaches the start of the fourth quarter of 2027 only if quarterly cash burn stops rising.
Unchanged. The independent safety board is still set to complete the interim stroke analysis in the first quarter of 2027. Unlike prior quarters, when the target date slipped three times, the 200th patient is now enrolled, locking in the 90-day follow-up window.
Unchanged. DiaMedica again said that "R&D expenses will moderately increase in future periods relative to recent prior periods" as ReMEDy2 continues enrolling and the Canadian preeclampsia trial starts up. After a 13.4% jump to $9.2 million this quarter, another 5% rise would take fourth-quarter research spending to $9.7 million by our math.
Unchanged. The drugmaker expects overhead costs to hold steady near the recent $2.4 million quarterly level, which it has maintained for three straight quarters.
❓ Key Questions
What trial size does the Q4 2027 cash outlook assume?
With $34.9 million in cash and an $8.8 million quarterly burn rate, does funding "into Q4, 2027" assume the stroke trial stops at 300 patients rather than expanding toward 728?
Why did the rat lab reports miss the October target?
Management previously expected the rat exposure and activity reports in October to unlock a US preeclampsia application; what caused the delay to "the coming weeks"?
When will the first Canadian preeclampsia patient receive a dose?
The release dropped the prior target to dose the first Canadian patient by year-end; how many Canadian sites are active and when will dosing start?
How many patients are enrolled in ReMEDy2 beyond 200?
Sites keep recruiting during the 90-day follow-up window; what is the current monthly enrollment pace and how many active sites contributed patients this quarter?